kimblr.com

With Monday night’s last-minute change to Lafayette’s smoking ban, restaurants that cater to both smokers and families are left with a tough choice — families and no smoking or smoking and no families. What are local restaurants going to do?
For more, see the Wednesday edition of the Journal & Courier.
If the pungent smells of bright tree blossoms are not enough to show that spring is finally here, evidence of one of the great journeys in nature is a sure sign.
During the past few weeks, monarch butterflies have reappeared in the Midwest as they progress on a 4,000 mile journey across North America from their winter habitat in Michoacan, Mexico.
The first official siting in Indiana was reported in western Tippecanoe County on April 20, according to journeynorth.org.
The habitat of the monarch butterfly, their eggs and larvae — or caterpillars — is under threat both in Mexico and the United States. Conservationists, entomologists and a growing number of concerned citizens and students are now working to preserve the future of the orange and black butterfly and its young.
For more see the Wednesday edition of the Journal & Courier.
Innovation, financial incentives and shaking off the fear of failure are important elements as Indiana and the United States try to continue making progress in the global game of advanced manufacturing.
That’s the message several speakers presented Tuesday during the seventh annual advanced manufacturing summit at Purdue University.
“We need the researchers. We need the bright people at Purdue … and we need the entrepreneurs — the people who will go out there and take a risk,” said Alan Hubbard, a former assistant for economic policy to President George Bush a former executive director of the Council on Competitiveness.
For more see the Wednesday edition of the Journal & Courier.

jconline.com

April 22 (Bloomberg) — Hillary Clinton criticizes Saudi oil wealth while her husband benefits from its largess. She opposes a Colombian trade agreement that he supports. And she condemns China while his foundation solicits donations there.
With a record like that, former President Bill Clinton could well be running against his wife instead of stumping for her. The couple's differences, and his frequent blowups on the campaign trail, though, haven't hurt much with her supporters. As the campaign heads into the Pennsylvania primary today, he still manages to excite voters in rural areas and small towns where she has her best chance for victory over Barack Obama.
“I don't think he's an issue, especially in Pennsylvania, where he's always been well-loved,'' said Clay Richards, assistant director of Quinnipiac University's Polling Institute in Hamden, Connecticut. “He's firing up the Clinton base and making sure they stay motivated.''
Clinton's stumbles on the campaign trail have sometimes put the focus more on him than her and cut into his popularity.
He angered blacks after Obama's South Carolina victory in January by noting Jesse Jackson had won there, too. He lost his temper in front of California Democrats when asked about former ally Bill Richardson's endorsement of Obama, 46, according to the San Francisco Chronicle. And he defended his wife for claiming she came under fire in Bosnia by falsely asserting she said it once “late at night when she was exhausted.''
`The Race Card'
Clinton yesterday accused the Obama campaign of playing “the race card on me'' after the South Carolina primary, a charge that drew a rebuke from Obama. Clinton told a Philadelphia radio station his comments were “twisted'' after he likened Obama's primary victory to Jackson's in 1988.
Clinton was asked if he regretted that comparison, after a Pennsylvania official said she felt he was marginalizing Obama as “the black candidate.''

bloomberg.com

OTTAWA and GATINEAU, QC, Jan. 30 /CNW/ - Liponex Inc (TSX:LPX), and ImaSight Inc., a commercial-stage medical device company marketing an innovative, cost effective digital radiology solution, announced today that they have entered into a non-binding letter of intent for a business combination following which the current shareholders of ImaSight will own approximately 65% of the combined company. Pursuant to the transaction, Liponex would acquire all of the issued and outstanding shares of ImaSight by way of share purchase or through such other transaction structure as may be determined by the mutual agreement of ImaSight and Liponex. Liponex and ImaSight will apply to list the combined company’s common shares for trading on a TSX Group exchange.”As previously announced, our Board of Directors and management have been pursuing strategic options to leverage Liponex’s assets and resources. That process has led our Board of Directors to believe that this proposed business combination with ImaSight is the best opportunity available to the Company to maximize value for our shareholders,” said David Evans, Chairman of Liponex. “We are particularly pleased that the combined company will continue the development of the Liponex CRD5 program in dyslipidemia which we continue to believe has potential value in the natural health product arena.”"ImaSight is excited about the opportunities this merger brings” said John Brooks, CEO of ImaSight. “This will bring additional resources to our marketing and production operations and we share the optimism around the CRD5 program.” The Transaction A special committee of the board of directors of Liponex was formed to consider strategic alternatives for Liponex, including this proposed transaction. The board of directors of Liponex has unanimously approved signing the non-binding letter of intent described in this release. The companies have agreed to an exclusivity period until February 13, 2008 in which to complete due diligence, work toward a definitive agreement and during which they shall not solicit other proposals.The transaction is currently expected to be completed in April 2008, following all necessary shareholder and regulatory approvals. Closing of the transaction will include a share consolidation, name change, the election of persons nominated by ImaSight to the Board of Directors of Liponex that are acceptable to Liponex and satisfy the necessary regulatory requirements and the appointment of John Brooks as CEO of the combined company. The letter of intent also provides that in addition to any regulatory or exchange escrow provisions that may apply, Liponex shares received by ImaSight shareholders shall be subject to a contractual escrow arrangement that will include cancellation provisions in the event of certain dilutive corporate transactions undertaken after closing. Conditions Precedent and Required Approvals The letter of intent is non-binding and the proposed transaction remains subject to the completion of due diligence, the entering into of a definitive agreement and the satisfaction of closing conditions to be included in a definitive agreement, including listing and other necessary regulatory approvals and the receipt of a fairness opinion by the Liponex board. The transaction will also be conditional upon, among other things, the approval of both the Liponex and ImaSight shareholders and Liponex shareholders will be asked to vote on this transaction at an Annual and Special Meeting expected to be scheduled for April 2008. We cannot assure you that the transaction will be completed as proposed or at all.A more detailed description of the transaction structure and of the two companies will be contained in the definitive agreement and in a proxy circular that will be mailed to Liponex shareholders. Once mailed, the proxy circular will be available at www.sedar.com. All shareholders are urged to read the proxy circular once it is available. Investors are cautioned that, except as disclosed in the proxy circular to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Liponex should be considered highly speculative. About ImaSight and its Digital Radiography System ImaSight markets its patented digital x-ray sensor at a price affordable to veterinarians and chiropractors. Its hospital grade sensor has been approved for sale by Health Canada. Further information can be found at www.imasight.com About Liponex and CRD5 Liponex is a Biopharmaceutical development company developing natural source products for the treatment of cholesterol and metabolic disease. CRD5, its lead product, has undergone a number of human clinical trials under approval of Health Canada’s Natural Health Products Directorate with a primary goal of increasing HDL “good cholesterol”. This news release contains certain “forward-looking statements” and “forward-looking information” which may include but is not limited to statements in respect of Liponex’s and ImaSight’s future financial position or operations and the potential value of CRD5 in the natural health product arena. Words like “believe”, “intend”, “may”, “expect”, “anticipate”, “plan”, “should” and other similar expressions are forward-looking statements that involve a number of risks and uncertainties. By their nature, forward-looking statements involve numerous factors, assumptions and estimates. Some but not all of the factors that could cause actual results to differ materially from those projected in our forward-looking statements include among others: <
For a further description of the principal risks affecting Liponex, see Liponex’s regulatory filings at www.sedar.com. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward looking statements. Although Liponex and ImaSight have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and neither Liponex nor ImaSight undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof. The TSX does not accept responsibility for the adequacy or accuracy ofthis release. %SEDAR: 00022196E

newswire.ca